Shire sues Barr over Fosrenol patents
This article was originally published in Scrip
Executive Summary
Shire has filed suit in the US District Court for the Southern District of New York against Barr Laboratories, alleging patent infringement related to its generic version of Fosrenol (lanthanum carbonate), thus triggering the 30-month stay of approval while the legal challenge is fought. The lawsuit was expected, as Shire stated last month that it had received notices from both Barr and Mylan Laboratories related to paragraph IV challenges and was reviewing both notices.